Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 225-242

  Ascher Svanum, Haya ^a   Lage, Maureen J ^b   Perez Nieves, Magaly ^a   Reaney, Matthew D ^a,d   Lorraine, Joanne ^a   Rodriguez, Angel ^c   Treglia, Michael ^b  

^a ELI LILLY AND COMPANY   (United States)

^b HealthMetrics Outcomes Research   (United States)

^c ELI LILLY AND COMPANY   (Spain)

^d Eli Lilly Canada ^*  (United Kingdom)

Author keywords

Costs; Early discontinuation; Insulin; Persistence; Restart; Type 2 diabetes mellitus

Indexed keywords

INSULIN;

ADULT; AGE; ALCOHOL ABUSE; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DEMENTIA; DEPRESSION; DRUG COST; DRUG WITHDRAWAL; EMERGENCY CARE; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INSULIN TREATMENT; KAPLAN MEIER METHOD; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84926018773     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0065-z     Document Type: Article

References (29)

1. International Diabetes Foundation. IDF Diabetes Atlas. 6th ed; 2013. http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf (last accessed Jan 26, 2014).
2. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metrics. 2010;8:29.
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–46.
4. Centers for Disease Control and Prevention. CDC—fast facts on diabetes—2011 National Diabetes Fact Sheet—publications—diabetes DDT [Internet]. Centers for Disease Control and Prevention; 2013. http://www.cdc.gov/diabetes/pubs/factsheet11/fastfacts.htm (last accessed Jan 26, 2014).
5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Suppl 1):S67–74.
6. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran pathologic basis of disease. Philadelphia: Elsevier Saunders; 2005.
7. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
9. Nichols GA, Kimes TM, Harp JB, Kou TD, Brodovicz KG. Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care. 2012;35:495–7.
10. Oguz A, Benroubi M, Brismar K, et al. Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study. Curr Med Res Opin. 2013;29:911–20.
11. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24:1411–5.
12. Catalan VS, Couture JA, LeLorier J. Predictors of persistence of use of the novel antidiabetic agent acarbose. Arch Intern Med. 2001;161:1106–12.
13. D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med. 1993;32:382–7.
14. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–9.
15. U.S. Bureau of Labor Statistics [Internet]. http://bls.gov/ (last accessed Jan 26, 2014).
16. Heckman JJ. Sample selection bias as a specification error. Econometrica. 1979;47:153–61.
17. Griswold M, Parmigiani G, Potoskey A, Lipscomb J. Analyzing health care costs: a comparison of statistical methods motivated by Medicare colorectal cancer charges. Biostatistics. 2004;1:1–23.
18. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17:25–39.
19. Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther. 1999;21:1045–57.
20. Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ. 2005;31:240–50.
21. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31:2398–403.
22. Bogner HR, Morales KH, de Vries HF, Cappola AR. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10:15–22.
23. Tunis SL, Ascher-Svanum H, Stensland M, Kinon BJ. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. Pharmacoeconomics. 2004;22:1–8.
24. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25:2958–71.
25. Breitscheidel L, Stamenitis S, Dippel F-W, Schöffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ. 2010;13:8–15.
26. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–24.
27. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35:1279–84.
28. Ho P, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–41.
29. Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health. 2009;12:915–22.